AUTHOR=Romero-Ibarguengoitia Maria Elena, González-Cantú Arnulfo, Pozzi Chiara, Levi Riccardo, Mollura Maximiliano, Sarti Riccardo, Sanz-Sánchez Miguel Ángel, Rivera-Salinas Diego, Hernández-Ruíz Yodira Guadalupe, Armendariz-Vázquez Ana Gabriela, Del Rio-Parra Gerardo Francisco, Barco-Flores Irene Antonieta, González-Facio Rosalinda, Azzolini Elena, Barbieri Riccardo, de Azevedo Dias Alessandro Rodrigo, Henriques Guimarães Júnior Milton, Bastos-Borges Alessandra, Acciardi Cecilia, Paez-Bo Graciela, Teixeira Mauro Martins, Rescigno Maria TITLE=Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countries JOURNAL=Frontiers in Immunology VOLUME=13 YEAR=2022 URL=https://www.frontiersin.org/articles/10.3389/fimmu.2022.894277 DOI=10.3389/fimmu.2022.894277 ISSN=1664-3224 ABSTRACT=BackgroundScarce information exists in relation to the comparison of seroconversion and adverse events following immunization (AEFI) with different SARS-CoV-2 vaccines. Our aim was to correlate the magnitude of the antibody response to vaccination with previous clinical conditions and AEFI.MethodsA multicentric comparative study where SARS-CoV-2 spike 1-2 IgG antibodies IgG titers were measured at baseline, 21-28 days after the first and second dose (when applicable) of the following vaccines: BNT162b2 mRNA, mRNA-1273, Gam-COVID-Vac, Coronavac, ChAdOx1-S, Ad5-nCoV and Ad26.COV2. Mixed model and Poisson generalized linear models were performed.ResultsWe recruited 1867 individuals [52 (SD 16.8) years old, 52% men]. All vaccines enhanced anti-S1 and anti-S2 IgG antibodies over time (p<0.01). The highest increase after the first and second dose was observed in mRNA-1273 (p<0.001). There was an effect of previous SARS-CoV-2 infection; and an interaction of age with previous SARS-CoV-2 infection, Gam-COVID-Vac and ChAdOx1-S (p<0.01). There was a negative correlation of Severe or Systemic AEFI (AEs) of naïve SARS-CoV-2 subjects with age and sex (p<0.001); a positive interaction between the delta of antibodies with Gam-COVID-Vac (p=0.002). Coronavac, Gam-COVID-Vac and ChAdOx1-S had less AEs compared to BNT162b (p<0.01). mRNA-1273 had the highest number of AEFIs. The delta of the antibodies showed an association with AEFIs in previously infected individuals (p<0.001).ConclusionsThe magnitude of seroconversion is predicted by age, vaccine type and SARS-CoV-2 exposure. AEs are correlated with age, sex, and vaccine type. The delta of the antibody response only correlates with AEs in patients previously exposed to SARS-CoV-2.Registration numberClinicalTrials.gov, identifier NCT05228912.